Compare Cisco Systems Inc (CSCO) vs Pfizer Inc (PFE) Price & Performance

Cisco Systems (CSCO) trades at $117.09, down 3.48% over 24 hours, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.06 exceeding the $1.03 estimate. Revenue for 2025 was $56.65 billion, with a net income margin of 19.69%. Recent news highlights Cisco's strategic AI and cybersecurity partnerships, positioning it for growth in the networking and security markets.

The outlook for CSCO is positive, supported by analyst consensus with a $130.38 price target and 52% buy ratings. Key opportunities include AI-driven security demand and solid cash flow. Risks involve competitive pressures and debt levels, with a debt-to-asset ratio of 22.97% in 2025. Investors should weigh strong fundamentals against market volatility and execution risks.

Pfizer (PFE) trades at $24.25, up 0.33% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.75, beating expectations, and maintains a dividend of $0.43 per share. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, with key catalysts expected in 2026. Financials show revenue of $62.58B in 2025, with a net income margin of 11.83% and a P/E ratio of 18.69.

The outlook for Pfizer is mixed, with analyst consensus leaning toward Hold (58.98%) but a price target of $28.78 suggesting potential upside. Investment opportunities include a strong dividend yield and pipeline advancements, while risks involve patent cliffs and competitive pressures. The stock's current valuation appears reasonable, but execution on pipeline developments is critical for future growth.